Acceleron: When Bad News Is Really Good News
June 13, 2017 at 10:02 AM EDT
Acceleron has discontinued development of a kidney cancer after it failed in a clinical trial. Yet the drug maker's stock is on the rise today. Here's why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|